| Literature DB >> 34066811 |
Heeyeon Kim1, Yun-Ho Roh2, Seo-Hee Yoon1.
Abstract
Early diagnosis and treatment of bacterial meningitis in children are essential, due to the high mortality and morbidity rates. However, lumbar puncture is often difficult, and cerebrospinal fluid (CSF) culture takes time. This meta-analysis aims to determine the diagnostic accuracy of blood procalcitonin for detecting bacterial meningitis in children. We conducted a systematic search on electronic databases to identify relevant studies. Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were calculated, and a hierarchical summary receiver operating characteristic curve and area under the curve (AUC) were determined. Eighteen studies with 1462 children were included in the analysis. The pooled sensitivity, specificity, and the DOR of blood procalcitonin for detecting bacterial meningitis were 0.87 (95% confidence interval (CI): 0.78-0.93); 0.85 (95% CI: 0.75-0.91), and 35.85 (95% CI: 10.68-120.28), respectively. The AUC for blood procalcitonin was 0.921. Blood procalcitonin also showed higher diagnostic accuracy for detecting bacterial meningitis than other conventional biomarkers, including serum C-reactive protein and leukocyte count, CSF leukocyte and neutrophil count, and CSF protein and glucose levels. Blood procalcitonin can be a good supplemental biomarker with high diagnostic accuracy in detecting bacterial meningitis in children.Entities:
Keywords: bacterial meningitis; children; diagnosis; meta-analysis; procalcitonin; systematic review
Year: 2021 PMID: 34066811 PMCID: PMC8151301 DOI: 10.3390/diagnostics11050846
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1The flow diagram of the search and selection process.
Characteristics of the included studies.
| First Author (Year), Reference | Country | BM ( | Non-BM ( | Sample Type | Cutoff (ng/mL) | PCT Assay | Time of PCT Assessment |
|---|---|---|---|---|---|---|---|
| Gendrel (1997) [ | France | 18 | 41 | Plasma | 5 | LUMItest PCT (Brahms Diagnostica, Berlin, Germany) | On admission |
| Dubos-1 (2006) [ | France | 18 | 134 | Serum | 0.5 | LUMItest PCT (Brahms Diagnostica, Berlin, Germany) | On admission |
| Dubos-2 (2006) [ | France | 18 | 134 | Serum | 0.2 | LUMItest PCT (Brahms Diagnostica, Berlin, Germany) | On admission |
| Dubos (2008) [ | Switzerland, France, Spain, Turkey, Poland | 90 | 100 | Serum | 0.5 | Lumitest PCT (Brahms Diagnostica, Berlin, Germany) | On admission |
| Onal (2008) [ | Turkey | 16 | 14 | Plasma | 0.5 | Lumitest PCT (Brahms Diagnostica, Berlin, Germany) | On admission |
| Ibrahim (2011) [ | KSA | 18 | 20 | Serum | 0.5 | Immunoluminometric assay (Brahms Diagnostica, Berlin, Germany) | On admission |
| Alkholi-1 (2011) [ | Egypt | 20 | 20 | Serum | 2 | Lumitest PCT (Brahms Diagnostica, Berlin, Germany) | On diagnosis |
| Alkholi-2 (2011) [ | Egypt | 20 | 20 | Serum | 10 | Lumitest PCT (Brahms Diagnostica, Berlin, Germany) | On diagnosis |
| Monsef (2012) [ | Iran | 8 | 32 | Serum | 0.5 | Lumitest PCT (Brahms Diagnostica, Berlin, Germany) | Before antibiotic therapy |
| Mayah (2013) [ | Egypt | 24 | 44 | Serum | 3.3 | Lumitest PCT (Brahms Diagnostica, Berlin, Germany) | On admission |
| Umran (2014) [ | Iraq | 29 | 16 | Serum | 0.05 | ELIZA M6 (NA, USA) | On admission |
| Sanaei Dashti (2017) [ | Iran | 12 | 27 | Serum | 0.6 | Human PCT ELISA (BT Laboratory, Shanghai, China) | On admission |
| El Shorbagy-1 (2018) [ | KSA | 24 | 41 | Serum | 2 | Lumitest PCT (Brahms Diagnostica, Berlin, Germany) | On diagnosis |
| El Shorbagy-2 (2018) [ | KSA | 24 | 41 | Serum | 10 | Lumitest PCT (Brahms Diagnostica, Berlin, Germany) | On diagnosis |
| Chaudhary (2018) [ | Nepal | 22 | 26 | Serum | 0.5 | Maglumi PCT (Snibe Diagnostics, Shenzhen, China) | On admission |
| Garcia-1 (2018) [ | Spain | 7 | 165 | NA | 0.5 | NA | At the time of ED visit |
| Garcia-2 (2018) [ | Spain | 7 | 165 | NA | 2 | NA | At the time of ED visit |
| Zhang (2019) [ | China | 29 | 18 | Serum | 5.91 | VIDAS BRAHMS PCT (Biomerieux, Marcy l’Etoile, France) | On admission |
BM, bacterial meningitis; ED, emergency department; KSA, Kingdom of Saudi Arabia; NA, not available; PCT, procalcitonin.
Figure 2Summary of the risk of bias of the included studies (Quality assessment of the diagnostic accuracy studies-2, QUADAS-2).
Figure 3Coupled forest plots for sensitivity and specificity.
Figure 4Hierarchical summary receiver operating characteristic (HSROC) curve of the diagnostic performance of procalcitonin for diagnosing pediatric bacterial meningitis. The area under the curve of the HSROC was 0.921.
Figure 5Deeks’ funnel plot for publication bias. ESS = effective sample size.
Summary estimates of the diagnostic accuracy of procalcitonin for diagnosis of bacterial meningitis according to the cutoff value.
| Cutoff | Number of Studies | Sensitivity | Specificity | LR+ | LR− | DOR | AUC |
|---|---|---|---|---|---|---|---|
| ≤0.5 pg/mL | 9 | 0.899 | 0.844 | 5.763 | 0.12 | 48.157 | 0.935 |
| >0.5 pg/mL | 9 | 0.831 | 0.851 | 5.577 | 0.199 | 28.084 | 0.908 |
AUC, area under the curve; CI, confidence interval; DOR, diagnostic odds ratio; LR+, positive likelihood ratio; LR−, negative likelihood ratio.
Summary estimates of the diagnostic accuracy for other biomarkers.
| Biomarkers | Number of Studies | Sensitivity | Specificity | LR+ (95% CI) | LR− (95% CI) | DOR (95% CI) |
|---|---|---|---|---|---|---|
| CRP | 10 | 0.797 | 0.725 | 2.894 | 0.28 | 10.334 |
| WBCs | 5 | 0.659 | 0.713 | 2.294 | 0.479 | 4.794 |
| CSF WBCs | 4 | 0.733 | 0.669 | 2.217 | 0.399 | 5.556 |
| CSF neutrophils | 4 | 0.793 | 0.749 | 3.158 | 0.277 | 11.403 |
| CSF protein | 4 | 0.838 | 0.658 | 2.452 | 0.247 | 9.934 |
| CSF glucose | 3 | 0.563 | 0.193 | 0.698 | 2.264 | 0.308 |
AUC, area under the curve; CI, confidence interval; CRP, C-reactive protein; CSF, cerebrospinal fluid; DOR, diagnostic odds ratio; LR+, positive likelihood ratio; LR−, negative likelihood ratio; WBC, white blood cell.